[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053538":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":41,"centralContacts":42,"locations":41,"responsibleParty":48,"collaborators":41,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":41,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":41,"enrollmentInfo":59,"targetDuration":41,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":41,"overallStatus":70,"whyStopped":41,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":41},{"fullName":5,"class":6},"Henan Cancer Hospital","OTHER_GOV",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Etoposide","EXPERIMENTAL","Etoposide: PO, 50 mg, d1-d14, Q3W",[13],"Drug: Toripalimab; Etoposide",{"label":15,"type":10,"description":16,"interventionNames":17},"Etoposide+Toripalimab","Toripalimab: 240 mg ,D1, ivgtt, Q3W; Etoposide: PO, 50 mg, d1-d14 ，Q3W；",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Toripalimab+Etoposide+Anlotinib","Toripalimab: 240 mg ,D1, ivgtt, Q3W; Etoposide: PO, 50 mg, d1-d14 ，Q3W； Anlotinib: 12mg, d1-d14, PO, Q3W;",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Toripalimab+Etoposide+Carboplatin","Toripalimab: 240 mg ,D1, ivgtt, Q3W; Etoposide: PO, 50 mg, d1-d14 ，Q3W； Carboplatin: AUC=5, d1, ivgtt, Q3W",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Etoposide+Toripalimab+Temozolomide","Toripalimab: 240 mg ,D1, ivgtt, Q3W; Etoposide: PO, 50 mg, d1-d14 ，Q3W； Temozolomide: 75mg\u002Fm ² \u002Fd, d1-d21, PO, Q4W;",[13],[31],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DRUG","Toripalimab; Etoposide","Toripalimab: 240 mg ,D1, ivgtt, Q3W; Etoposide: PO, 50 mg, d1-d14 ，Q3W； carboplatin: AUC=5，d1， ivgtt,， Q3W； temozolomide:75mg\u002Fm2\u002Fd，d1-d21，PO，Q4W; Anlotinib:12mg，d1-d14 PO，Q3W",[9,15,27,19,23],[37,38,39,40],"Etoposide；","carboplatin","temozolomide","Anlotinib",null,[43],{"name":44,"role":45,"phone":46,"phoneExt":41,"email":47},"Qiming Wang","CONTACT","4000371818","qimingwang1006@126.com",{"type":49,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR","100053538","phase-2-toripalimab-combined-with-beat-chemotherapy-in-the-treatment-of-advanced-back-line-small-cell-lung-cancer-100053538",false,"NCT07698054","Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer","A Prospective, Open-label, Bayesian Adaptive Randomized Phase II Clinical Study of Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer","Inclusion Criteria:\n\n* 1.Age ≥18 years old, both male and female are acceptable.\n* 2\\. Histology and pathology diagnosis of extensive stage small cell lung cancer, and must meet the following standards:\n\n  1. always has not received the immune therapy,\n  2. Previously received immunotherapy, with the number of treatment lines ≥2 and the immunotherapy being effective(immunotherapy PFS \\> 3 months, withdrawal time \\> 3 months)\n  3. never used anlotinib,\n* 3\\. ECOG: 0 \\~ 2;\n* 4 . The expected lifetime 12 weeks or more;\n* 5\\. Major organs function normal\n\nExclusion Criteria:\n\n* 1.Those who are allergic to toripalimab or etoposide or have metabolic disorders;\n* 2.With known the special ripley sheet resistance, etoposide contraindication;\n* 3.Other circumstances that the researcher assessed as unsuitable for participation in this clinical study.","ALL","18 Years",{"count":60,"type":61},130,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","This study is a randomized, open-label, multi-center investigator-initiated clinical trial. Patients who meet the inclusion criteria receive the treatment plan stipulated in the protocol. A Bayesian design is used to explore the efficacy and safety of teprotumumab combined with pulse chemotherapy in the treatment of advanced second-line extensive-stage small cell lung cancer.",[67,68,69],"SCLC, Extensive Stage","Bayesian","Metronomic Chemotherapy","NOT_YET_RECRUITING","2026-07-09",{"date":73,"type":74},"2026-07-13","ACTUAL",{"date":76,"type":61},"2026-08-01",{"date":78,"type":61},"2030-12-31",{"name":5,"class":6}]